Asia-Pacific Peripheral Neuropathy Treatment Market Trends, Size, Competitive Analysis and Forecast 2020-2026
Asia-Pacific peripheral neuropathy treatment market is estimated to grow at a CAGR of 5.1% during the forecast period. A significant rise in cancer prevalence is one of the major factors accelerating the demand for peripheral neuropathy treatment in the region. As per the World Health Organization (WHO), the number of new cancer incidences in China was nearly 4.3 million in 2018. Additionally, the number of new cancer incidences in India was nearly 1.1 million in 2018. Chemotherapy is most often used for cancer treatment, which is significantly associated with the risk of developing chemotherapy-induced peripheral neuropathy (CIPN). Chemotherapy is used to destroy rapidly growing cancer cells in the body. The condition has been anticipated to be high in patients who received treatment with any neurotoxic chemotherapeutic agent. CIPN is normally treated with anticonvulsants, analgesics, and antidepressants. Topical agents including lidocaine are often used, and opioids can also be used in cases that involve extreme pain.
To Request a Sample of our Report on Asia-Pacific Peripheral Neuropathy Treatment Market: https://www.omrglobal.com/request-sample/asia-pacific-peripheral-neuropathy-treatment-market
Scope of the
Asia-Pacific Peripheral Neuropathy Treatment Market
Market
Coverage
·
Market
number available for 2019-2026
·
Base
year- 2019
·
Forecast
period- 2020-2026
·
Segment
Covered- By Type and Application
·
Countries
Covered- China, India, Japan, and Rest of Asia-Pacific
·
Competitive
Landscape- Alembic Pharmaceuticals Ltd., Cipla Ltd., Daiichi Sankyo Company,
Ltd., and Pfizer Inc.
Recent
Strategic Initiatives in the Asia-Pacific Peripheral Neuropathy Treatment
Market
·
In
April 2019, Daiichi Sankyo Company, Ltd. declared the launch of Tarlige tablets
for pain treatment in Japan. In Japan 2019, ?2? ligand drug was approved in
Japan for marketing based on phase 3 clinical trials results performed in Asia,
for patients suffering from diabetic peripheral neuropathic pain, postherpetic
neuralgia (PHN), for the treatment of peripheral neuropathic pain.
·
In July
2019, Cipla declared that InvaGen Pharmaceuticals, its subsidiary gained US
approval for Pregabalin Capsules, which is intended for neuropathic pain
management associated with some illnesses. InvaGen gained approval from the US
FDA for the drug in the strengths of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg,
225mg and 300mg.
Key questions
addressed by the report
·
What is
the market growth rate?
·
Which
segment dominates the market in the base year?
·
Which
segment will project the fastest growth in the market?
·
How
COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID-19
forecast
o Most affected segment
·
Who is
the leader in the market?
·
How
players are addressing challenges to sustain growth?
·
Where
is the investment opportunity?
(Get 15% Discount on Buying this Report)
A full
Report of Asia-Pacific Peripheral Neuropathy Treatment Market is Available
at: https://www.omrglobal.com/industry-reports/asia-pacific-peripheral-neuropathy-treatment-market
·
Antidepressants
·
Pain
Relievers
·
Antiseizure
·
Others
By
Application
·
Diabetes
·
Chemotherapy-Induced
·
Others
Asia-Pacific
Peripheral Neuropathy Treatment Market– Segment by Country
·
China
·
India
·
Japan
Rest of
Asia-Pacific
Company
Profiles
·
Alembic
Pharmaceuticals Ltd.
·
Bristol
Myers Squibb Co.
·
Cipla
Ltd.
·
Daiichi
Sankyo Company, Ltd.
·
Eli
Lilly and Co.
·
Glenmark
Pharmaceuticals Ltd.
·
Lupin,
Ltd.
·
Mylan
N.V.
·
Novartis
International AG
·
Pfizer,
Inc.
Reasons for Buying from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More
Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-peripheral-neuropathy-treatment-market
About Orion
Market Research
Orion Market Research (OMR) is a market
research and consulting company known for its crisp and concise reports. The
company is equipped with an experienced team of analysts and consultants. OMR
offers quality syndicated research reports, customized research reports, consulting
and other research-based services.
For More Information, Visit Orion Market Research
Media Contact:
Company Name: Orion Market
Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment